Effectiveness of neoadjuvant chemotherapy with a docetaxel, cisplatin, and S-1 (DCS) regimen for T4b gastric cancer
Abstract Background No studies on neoadjuvant chemotherapy for gastric cancer (GC) with T4b stage were reported. This study aimed to assess the effectiveness of neoadjuvant chemotherapy using DCS regimen (docetaxel, cisplatin, and S-1) for GC with T4b stage. Methods Forty-three patients diagnosed GC...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-12-01
|
| Series: | World Journal of Surgical Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12957-024-03620-1 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850102089488793600 |
|---|---|
| author | Vo Duy Long Dang Quang Thong Tran Quang Dat Doan Thuy Nguyen Tran Duy Phuoc Nguyen Viet Hai Nguyen Lam Vuong Lam Quoc Trung Nguyen Hoang Bac |
| author_facet | Vo Duy Long Dang Quang Thong Tran Quang Dat Doan Thuy Nguyen Tran Duy Phuoc Nguyen Viet Hai Nguyen Lam Vuong Lam Quoc Trung Nguyen Hoang Bac |
| author_sort | Vo Duy Long |
| collection | DOAJ |
| description | Abstract Background No studies on neoadjuvant chemotherapy for gastric cancer (GC) with T4b stage were reported. This study aimed to assess the effectiveness of neoadjuvant chemotherapy using DCS regimen (docetaxel, cisplatin, and S-1) for GC with T4b stage. Methods Forty-three patients diagnosed GC with surgical or clinical T4b stage received three or four preoperative cycles of DCS therapy followed by gastrectomy and lymphadenectomy between Jan-2018 and Dec-2022. Short-tern outcomes including tumor response, completion of neoadjuvant chemotherapy, toxicity and adverse events, rate of treatment-related death, R0 resection, rate of complete adjuvant chemotherapy and short-term surgical results were investigated. The oncologic outcomes comprised 3-year OS and 3-year disease-free survival (DFS). Results A total of 43 patients with T4b gastric cancer were included in the analysis. Among them, twenty-five patients underwent gastrectomy and lymphadenectomy. The completion rate of neoadjuvant chemotherapy was 88.4%, including 4 cycles of 51.2% and 3 cycles of 37.2%. The disease-control and clinical response rate were 88.4% and 58.1%, respectively. During preoperative chemotherapy, grade 3/4 neutropenia occurred in 20.9%, anemia in 13.9%, hyponatremia in 4.8%, and vomiting in 2.3%. Pathologic complete response was achieved in 8.0%. After surgery, no patient experienced severe complications (Clavien Dindo > = 3). The R0 resection rate was 72.0% and the rate of complete adjuvant chemotherapy was 83.3%. The 3-year OS and DFS rates were 49% and 38%, respectively. Conclusions Neoadjuvant chemotherapy with DCS regimen demonstrated a high tolerance, high tumor response rate, high complete adjuvant chemotherapy rate and satisfactory 3-year survival outcomes. Three- or four-course of preoperative DCS regimen is a promising approach for GC with T4b stage. |
| format | Article |
| id | doaj-art-0125b6ca59fc4a2eb0dd5aa9c550d1bb |
| institution | DOAJ |
| issn | 1477-7819 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | BMC |
| record_format | Article |
| series | World Journal of Surgical Oncology |
| spelling | doaj-art-0125b6ca59fc4a2eb0dd5aa9c550d1bb2025-08-20T02:39:49ZengBMCWorld Journal of Surgical Oncology1477-78192024-12-0122111110.1186/s12957-024-03620-1Effectiveness of neoadjuvant chemotherapy with a docetaxel, cisplatin, and S-1 (DCS) regimen for T4b gastric cancerVo Duy Long0Dang Quang Thong1Tran Quang Dat2Doan Thuy Nguyen3Tran Duy Phuoc4Nguyen Viet Hai5Nguyen Lam Vuong6Lam Quoc Trung7Nguyen Hoang Bac8Department of Gastro-intestinal Surgery, University Medical Center, University of Medicine and Pharmacy at Ho Chi Minh CityDepartment of Gastro-intestinal Surgery, University Medical Center, University of Medicine and Pharmacy at Ho Chi Minh CityDepartment of Gastro-intestinal Surgery, University Medical Center, University of Medicine and Pharmacy at Ho Chi Minh CityDepartment of Gastro-intestinal Surgery, University Medical Center, University of Medicine and Pharmacy at Ho Chi Minh CityDepartment of General Surgery, Faculty of Medicine, University of Medicine and Pharmacy at Ho Chi Minh CityDepartment of Gastro-intestinal Surgery, University Medical Center, University of Medicine and Pharmacy at Ho Chi Minh CityDepartment of Medical Statistics and Informatics, Faculty of Public Health, University of Medicine and Pharmacy at Ho Chi Minh CityDepartment of Oncology, University Medical Center, University of Medicine and Pharmacy at Ho Chi Minh CityDepartment of Gastro-intestinal Surgery, University Medical Center, University of Medicine and Pharmacy at Ho Chi Minh CityAbstract Background No studies on neoadjuvant chemotherapy for gastric cancer (GC) with T4b stage were reported. This study aimed to assess the effectiveness of neoadjuvant chemotherapy using DCS regimen (docetaxel, cisplatin, and S-1) for GC with T4b stage. Methods Forty-three patients diagnosed GC with surgical or clinical T4b stage received three or four preoperative cycles of DCS therapy followed by gastrectomy and lymphadenectomy between Jan-2018 and Dec-2022. Short-tern outcomes including tumor response, completion of neoadjuvant chemotherapy, toxicity and adverse events, rate of treatment-related death, R0 resection, rate of complete adjuvant chemotherapy and short-term surgical results were investigated. The oncologic outcomes comprised 3-year OS and 3-year disease-free survival (DFS). Results A total of 43 patients with T4b gastric cancer were included in the analysis. Among them, twenty-five patients underwent gastrectomy and lymphadenectomy. The completion rate of neoadjuvant chemotherapy was 88.4%, including 4 cycles of 51.2% and 3 cycles of 37.2%. The disease-control and clinical response rate were 88.4% and 58.1%, respectively. During preoperative chemotherapy, grade 3/4 neutropenia occurred in 20.9%, anemia in 13.9%, hyponatremia in 4.8%, and vomiting in 2.3%. Pathologic complete response was achieved in 8.0%. After surgery, no patient experienced severe complications (Clavien Dindo > = 3). The R0 resection rate was 72.0% and the rate of complete adjuvant chemotherapy was 83.3%. The 3-year OS and DFS rates were 49% and 38%, respectively. Conclusions Neoadjuvant chemotherapy with DCS regimen demonstrated a high tolerance, high tumor response rate, high complete adjuvant chemotherapy rate and satisfactory 3-year survival outcomes. Three- or four-course of preoperative DCS regimen is a promising approach for GC with T4b stage.https://doi.org/10.1186/s12957-024-03620-1Gastric cancerNeoadjuvant chemotherapyT4b stageClinical response rateDCS regimen |
| spellingShingle | Vo Duy Long Dang Quang Thong Tran Quang Dat Doan Thuy Nguyen Tran Duy Phuoc Nguyen Viet Hai Nguyen Lam Vuong Lam Quoc Trung Nguyen Hoang Bac Effectiveness of neoadjuvant chemotherapy with a docetaxel, cisplatin, and S-1 (DCS) regimen for T4b gastric cancer World Journal of Surgical Oncology Gastric cancer Neoadjuvant chemotherapy T4b stage Clinical response rate DCS regimen |
| title | Effectiveness of neoadjuvant chemotherapy with a docetaxel, cisplatin, and S-1 (DCS) regimen for T4b gastric cancer |
| title_full | Effectiveness of neoadjuvant chemotherapy with a docetaxel, cisplatin, and S-1 (DCS) regimen for T4b gastric cancer |
| title_fullStr | Effectiveness of neoadjuvant chemotherapy with a docetaxel, cisplatin, and S-1 (DCS) regimen for T4b gastric cancer |
| title_full_unstemmed | Effectiveness of neoadjuvant chemotherapy with a docetaxel, cisplatin, and S-1 (DCS) regimen for T4b gastric cancer |
| title_short | Effectiveness of neoadjuvant chemotherapy with a docetaxel, cisplatin, and S-1 (DCS) regimen for T4b gastric cancer |
| title_sort | effectiveness of neoadjuvant chemotherapy with a docetaxel cisplatin and s 1 dcs regimen for t4b gastric cancer |
| topic | Gastric cancer Neoadjuvant chemotherapy T4b stage Clinical response rate DCS regimen |
| url | https://doi.org/10.1186/s12957-024-03620-1 |
| work_keys_str_mv | AT voduylong effectivenessofneoadjuvantchemotherapywithadocetaxelcisplatinands1dcsregimenfort4bgastriccancer AT dangquangthong effectivenessofneoadjuvantchemotherapywithadocetaxelcisplatinands1dcsregimenfort4bgastriccancer AT tranquangdat effectivenessofneoadjuvantchemotherapywithadocetaxelcisplatinands1dcsregimenfort4bgastriccancer AT doanthuynguyen effectivenessofneoadjuvantchemotherapywithadocetaxelcisplatinands1dcsregimenfort4bgastriccancer AT tranduyphuoc effectivenessofneoadjuvantchemotherapywithadocetaxelcisplatinands1dcsregimenfort4bgastriccancer AT nguyenviethai effectivenessofneoadjuvantchemotherapywithadocetaxelcisplatinands1dcsregimenfort4bgastriccancer AT nguyenlamvuong effectivenessofneoadjuvantchemotherapywithadocetaxelcisplatinands1dcsregimenfort4bgastriccancer AT lamquoctrung effectivenessofneoadjuvantchemotherapywithadocetaxelcisplatinands1dcsregimenfort4bgastriccancer AT nguyenhoangbac effectivenessofneoadjuvantchemotherapywithadocetaxelcisplatinands1dcsregimenfort4bgastriccancer |